Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)

International Journal of Cancer

Volumn 138, Issue 3, 2016, Pages 739-746

  Stahler, A ^a,b   Heinemann, V ^a,c   Giessen Jung, C ^a   Crispin, A ^b   Schalhorn, A ^a   Stintzing, S ^a,c   Fischer Von Weikersthal, L ^d   Vehling Kaiser, U ^e   Stauch, M ^f   Quietzsch, D ^g   Held, S ^h   Von Einem, J C ^a   Holch, J ^a   Neumann, J ^b,c   Kirchner, T ^b,c   Jung, A ^b,c   Modest, D P ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d KLINIKUM ST MARIEN   (Germany)

^e Onkologische Praxis   (Germany)

^f Praxis für Hämatologie und Internistische Onkologie   (Germany)

^g KLINIKUM CHEMNITZ   (Germany)

^h CLINASSESS GMBH   (Germany)

Author keywords

AREG; EREG; metastatic colorectal cancer; RAS

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; CAMPTOTHECIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PLATINUM COMPLEX;

ADULT; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; ONCOGENE; ONCOGENE RAS; OVERALL SURVIVAL; PI3KCA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; GENETICS; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AMPHIREGULIN; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; EPIREGULIN; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; RNA, MESSENGER;

EID: 84955627843     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29807     Document Type: Article

References (25)

1. Amado RG, Wolf M, Peeters M, et al., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
2. Douillard JY, Siena S, Cassidy J, et al., Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-705.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, et al., K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
4. Van Cutsem E, Kohne CH, Lang I, et al., Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9.
5. Douillard JY, Oliner KS, Siena S, et al., Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34.
6. Heinemann V, von Weikersthal LF, Decker T, et al., FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-75.
7. Schwartzberg LS, Rivera F, Karthaus M, et al., PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-7.
8. Baker JB, Dutta D, Watson D, et al., Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 2011; 104: 488-95.
9. Jacobs B, De Roock W, Piessevaux H, et al., Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009; 27: 5068-74.
10. Jonker DJ, Karapetis CS, Harbison C, et al., Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br J Cancer 2014; 110: 648-55.
11. Khambata-Ford S, Garrett CR, Meropol NJ, et al., Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-7.
12. Pentheroudakis G, Kotoula V, De Roock W, et al., Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 2013; 13: 49
13. Yamada M, Ichikawa Y, Yamagishi S, et al., Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer Res 2008; 14: 2351-6.
14. Yoshida M, Shimura T, Sato M, et al., A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol 2013; 139: 367-78.
15. Seligmann J., Combined epiregulin (EREG) and amphiregulin (AREG) expression levels as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC). J Clin Oncol 2014; 32 (suppl; abstr 3520): 5s.
16. Fischer von Weikersthal L, Schalhorn A, et al., Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 2011; 47: 206-14.
17. Giessen C, Fischer von Weikersthal L, et al., Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial. Br J Cancer 2013; 109: 1428-36.
18. Neumann J, Zeindl-Eberhart E, Kirchner T, et al., Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009; 205: 858-62.
19. Neumann J, Wehweck L, Maatz S, et al., Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Archiv Int J Pathol 2013; 463: 509-23.
20. Kuramochi H, Nakajima G, Kaneko Y, et al., Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. BMC Cancer 2012; 12: 88.
21. Roth AD, Tejpar S, Delorenzi M, et al., Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74.
22. Stintzing S, Fischer von Weikersthal L, et al., FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol 2012; 23: 1693-9.
23. Liao X, Morikawa T, Lochhead P, et al., Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012; 18: 2257-68.
24. Tol J, Dijkstra JR, Klomp M, et al., Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010; 46: 1997-2009.
25. Huang CW, Tsai HL, Chen YT, et al., The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer 2013; 13: 599.